Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
01:01pm, Thursday, 19'th Mar 2026
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Bamco Inc. NY
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ: XENE) by 46.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 30,0
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
09:51am, Friday, 13'th Mar 2026
Driehaus Capital Management increased its XENE stake by 369,577 shares in the fourth quarter; the estimated transaction value was $15.52 million. Meanwhile, the quarter-end position value rose by $36.
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
10:39pm, Tuesday, 10'th Mar 2026
VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
12:30pm, Tuesday, 10'th Mar 2026
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
07:00pm, Monday, 09'th Mar 2026
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were
Xenon Pharmaceuticals Announces Proposed Public Offering
04:01pm, Monday, 09'th Mar 2026
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,
Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge
02:50pm, Monday, 09'th Mar 2026
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index falling more than 300 points on Monday.
Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript
Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked
11:56am, Monday, 09'th Mar 2026
Xenon Pharmaceuticals Inc. surged on positive Phase 3 data for azetukalner in focal onset seizures, showing best-in-class placebo-adjusted efficacy. XENE plans an NDA submission for azetukalner in Q3
What's Going On With Biohaven Stock On Monday?
11:47am, Monday, 09'th Mar 2026
Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
09:26am, Monday, 09'th Mar 2026
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares are up during Monday's premarket session following the announcement of positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal
Xenon Pharma's epilepsy drug meets main goal in late-stage trial
07:26am, Monday, 09'th Mar 2026
Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of a late-stage trial, showing a statistically significant reduction in foc
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
07:00am, Monday, 09'th Mar 2026
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,
